Cardio- Renal Outcomes With Long- Term Agalsidase Alfa Enzyme Replacement Therapy: A 10- Year Fabry Outcome Survey (FOS) Analysis.
Uma RamaswamiMichael BeckDerralynn HughesChristoph KampmannJaco BothaGuillem Pintos-MorellMichael L WestDau-Ming NiuKathleen NichollsRoberto Giuglianinull nullPublished in: Drug design, development and therapy (2019)
Agalsidase alfa-treated patients with 10-year FOS data and preserved kidney function and/or normal LVMI at baseline remained largely stable; those with decreased kidney function or LVH at baseline experienced modest declines in renal function and/or increases in LVMI.